MECHANISMS OF PROTECTION FROM AND ENHANCED SUSCEPTIBILITY TO HIV INFECTION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 理解STEP/Phambili试验结果的关键是首先在使用恒河猴粘膜SIV接种的对照实验中模拟试验结果。因此，我们将确定默克三价HIV腺病毒5载体疫苗(V520)在恒河猴粘膜传播HIV模型中增强S1V易感性的有效性和潜力。如果建立了疫苗保护或增强的模型，与任何保护或增强效果相关的免疫机制和炎症/激活可以在更新申请中定义。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The key to understanding the results of the STEP/Phambili trials is first to model the results of the trial in controlled experiments using mucosal SIV inoculation of rhesus macaques. Thus, we will determine the effectiveness and potential of the Merck trivalent HIV adenovirus 5 vector vaccine (V520) for enhancing susceptibility to S1V in a rhesus macaque model of mucosal HIV transmission. If models of vaccine protection or enhancement are established, the immune mechanisms and inflammation/activation associated with any protective or enhancing effects can be defined in a renewal application.